Key Details
Price
$1.31Annual ROE
341.07%Beta
0.88Events Calendar
Next earnings date:
May 09, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath
Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months
Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout United States participating in the study LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
Publication of data relating to RenovoRx's targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal Publication of data relating to RenovoRx's targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal
Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer
New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai. Dear Fellow RenovoRx Shareholders, The first quarter of 2024 marked a significant period in our company's evolution, and we have set the stage for significant milestones in the foreseeable.
RenovoRx (NASDAQ: RNXT ) just reported results for the fourth quarter of 2023. RenovoRx reported earnings per share of -30 cents.
FAQ
- What is the primary business of RenovoRx?
- What is the ticker symbol for RenovoRx?
- Does RenovoRx pay dividends?
- What sector is RenovoRx in?
- What industry is RenovoRx in?
- What country is RenovoRx based in?
- When did RenovoRx go public?
- Is RenovoRx in the S&P 500?
- Is RenovoRx in the NASDAQ 100?
- Is RenovoRx in the Dow Jones?
- When was RenovoRx's last earnings report?
- When does RenovoRx report earnings?
- Should I buy RenovoRx stock now?